FDA Brief

Warning letters Drugs

FDA warning letter to

CytoDyn, Inc.

High riskIssued Feb 11, 2022Posted Feb 22, 2022The Office of Prescription Drug Promotion (OPDP)

FDA warns CytoDyn over video promoting unapproved leronlimab as safe and effective for COVID-19.

What happened

FDA's Office of Prescription Drug Promotion reviewed a September 22, 2021 video interview with Dr. Nader Pourhassan that was linked on CytoDyn's website. In the video, he promoted leronlimab, an investigational new drug, as safe and effective for COVID-19 and made claims about survival and trial results. FDA said leronlimab was not approved or authorized and that available data did not support clinical benefit for COVID-19.

What FDA found

  1. The video promoted leronlimab, an investigational drug, as safe and effective for COVID-19 before FDA approval or authorization.

    21 CFR 312.7(a)
  2. The promotional video described a prescription use without adequate directions for safe lay use, so leronlimab was misbranded.

    section 502(f)(1) of the FD&C Act
  3. The company's actions violated the FD&C Act by introducing or delivering a misbranded drug.

    section 301(a) of the FD&C Act
  4. The video made conclusory and misleading claims that mischaracterized clinical trial data for leronlimab in COVID-19.

    section 502(f)(1) of the FD&C Act

What FDA wants

OPDP asks CytoDyn to stop the violations and to send a written response within 15 working days of receipt. The response must address the concerns, list other promotional communications with similar claims, explain plans to discontinue them or cease distribution, and include a plan for corrective communications.

Who should pay attention

  • drug sponsors and investigators
  • medical communications and investor relations teams
  • clinicians and patients considering COVID-19 treatments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  3. Herbal Dermals LLC FZ dba Gotucream

    FDA warned Herbal Dermals LLC FZ dba Gotucream that its Gotucream balanitis cream is an unapproved new drug.

    Low
  4. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low